Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China ...Middle East

BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor...

Hence then, the article about jacobio out licensed kras g12c inhibitor glecirasib and shp2 inhibitor jab 3312 to allist in china was published today ( Friday 30/08/2024 - 02:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China )

Also on site :

• Road over canal in Penkridge closed as bridge reportedly collapses
• Disneyland Paris New Year’s Eve Fireworks Live Stream 2025–2026: Watch Here
• Police and air ambulance attend 'medical emergency' incident in Stourbridge